February 17, 2023

Guo-Liang Yu Chief Executive Officer Apollomics Inc. 989 E. Hillsdale Blvd., Suite 220 Foster City, CA 94404

Re: Apollomics Inc.
Amendment No. 3 to

Registration Statement on Form F-4

Filed February 10,

2023

File No. 333-268525

Dear Guo-Liang Yu:

 $\label{eq:weak_problem} \mbox{We have reviewed your amended registration statement and have the following}$

 $\,$ comment. In our comment, we may ask you to provide us with information so we may better

understand your disclosure.

 $\,\,$ Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe our comment applies to your facts and

circumstances or do not believe an amendment is appropriate, please tell us why in your $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

response.

 $\label{eq:After reviewing any amendment to your registration statement and the information you$

provide in response to these comments, we may have additional comments.

Amendment No. 3 to Registration Statement on Form F-4

Summary of the Proxy Statement/Prospectus Subscription Agreements, page 36

1. We note that certain accredited investors have entered into subscription agreements to

purchase Apollomics

Class B Ordinary Shares and Apollomics Series A Preferred Shares

in connection with the

business combination. Please further highlight the material

differences in the

terms and price of securities issued at the time of the IPO as compared to private placements

contemplated at the time of the business combination. Please also

disclose if any of

Maxpro's sponsors, directors, officers or their affiliates will

participate in this

private placement.

Guo-Liang Yu

FirstName

ApollomicsLastNameGuo-Liang Yu

Inc.

Comapany17,

February NameApollomics

2023 Inc.

February

Page 2 17, 2023 Page 2

 ${\tt FirstName \ LastName}$

You may contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494 if

you have questions regarding comments on the financial statements and related matters. Please $\,$

contact Tyler Howes at 202-551-3370 or Suzanne Hayes at 202-551-3675 with any other

questions.

Corporation Finance

Division of

Office of Life

Sciences cc: Daniel Nussen, Esq.